28/08/2015 23:15:26 Cookie Policy Free Membership Login

Ekf Diagnostics Share Price - EKF

Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change Price Change % Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.13 +0.56% 22.38 22.25 22.50 22.50 22.50 22.50 259,689 16:35:26
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m) RN NRN
Health Care Equipment & Services 40.1 -4.0 -1.5 - 94.44

Ekf Diagnostics News, Charts, Forums & Trades

More Ekf Diagnostics News
Ekf Diagnostics Takeover Rumours

Ekf Diagnostics Share Charts

1 Year Ekf Diagnostics Chart

1 Year Ekf Diagnostics Chart

1 Month Ekf Diagnostics Chart

1 Month Ekf Diagnostics Chart

Intraday Ekf Diagnostics Chart

Intraday Ekf Diagnostics Chart

Ekf Diagnostics Discussions and Chat

Ekf Diagnostics Top Chat Posts

DateSubject
08/5/2014
10:20
totaleclipse: Just to put in a tiny bit more information I heard that Selah sales people were being paid very high commissions per test to incentivize them. Like half! That's kind of excessive dont you think? If the reimbursers discovered that bit of information I would guess they would be less than happy as it suggests the margins are very wide and maybe the reason for the cut. >>Bigman. You spotted a good point. If we focus on the next driver for the EKF share price- i.e. the 6 months results, the sales will be enhanced by just the $0.5m you calculate for April and a further $1.5m for May and June- not sure if that is going to reignite the shares to recover their upward path. Anyone have any views on the 6 month numbers?
25/6/2015
08:59
cisk: Morning Wan Agree - Mgt will be judged on next month's update - but as we both know, it takes a long time to gain any sort of traction in diagnostics - in fact anything healthcare related - as my small holding in Deltex will attest to! Very interesting news re: Alere; given the already strong relationship between them and Ron's shareholding in both companies it would not be a surprise. However I'm in it for the long term and believe that the share price can be at multiples of its current level, so personally I wouldn't want to see them taken over at a price anywhere near the current share price. Hopefully patience will be my biggest ally...
18/8/2015
14:53
interstellar: Quite Cisk. But what's the Molecular Business worth. With the company valued at 90 odd million overall as I write this then the remainder must be worth around 20 million- or so the market thinks since the share price hasn't reacted at all. I always thought it a mistake for EKF to start moving way from POC as this kind of confirms it. Does anyone else get the feeling that DE is a bit- how should I put it- upset by the position he finds himself in now???
27/8/2015
11:29
kestelmill: Can someone help me understand this. The share price is pretty much as low as it has ever been. Therefore the shareholders who are asking for the company to be broken up are going to lose money if they sell as of today. So why not: i) sell or offload the bad bits, ii) give the company more time to grow. It's not as if Julian Baines and David Evans don't have the track record. I don't really understand what the major shareholders are hoping for if they are considering selling off the best part of the business.
28/1/2015
13:42
andrewbaker: I think that the stock overhang may now be in the past, or close to in the past, and the true value of the company's business may now be better appreciated through its share price. The recent news is good, and hopefully so will future news; such that the share price may in future properly reflect the potential that is there. This is one smaller company that I hold, and will continue so to do for the foreseeable future.
20/1/2015
08:54
garth: Currently valued at £100m if you include the debt - according to ADVN's notoriously reliable quick figures... They raised over £20 million last year from investors. Andrew et al, the share price has dropped below 4 year lows and continues to fall. On a share price chart level a change in sentiment could possibly bring a 50% rise. But at £100 million, what makes these good value? Comments appreciated. G.
02/4/2015
11:03
totaleclipse: One of my cynical thoughts on the outcome of this strategic review (seen it before, read the book, got the T shirt) is going to be a whole new set of company objectives, possibly a cash call to provide the funds to action, and new target goals for share price and target date leading to a re-definition of the share options to "motivate" executives to achieve. If that happens I will sell every share I possess and never trouble these pages again.
02/4/2015
08:44
totaleclipse: Well what a weird thing to actually do an official notice about. What it implies to me is that the board do not have confidence in the direction the executive team are taking the company - hence the need for a strategic review. MAybe Zwanziger is the driver for this having got closer to the substance behind the business. It is a huge negative in my book for why would it be needed if evrything was hunky dory- and why announce it except for the fact that it is probably going to affect the share price badly. I mean, don't get me wrong, but didn't the company executive, at the recent presentation in London, announce exactly what they were doing and what their goals were in this crucial 2015 year- just a couple of weeks ago! Begs the question- "what's changed?".
16/3/2015
07:46
wan: Overall I like the new tone and focus. There is a lot of strategic change that is now sunk cost and effort, but not yet evidenced in the share price, but as the management humbly acknowledge, that will only come with delivery, which they appear very confident in achieving. The revelation of private equity interest/enquiries would imply there is a 'lot' of upside to be realized, which the management have decided that they can deliver and can better deliver in terms of shareholder value......I like that!
19/3/2015
09:51
wan: It's very reassuring that again (as announced today) someone with such deep industry knowledge, such as the former Alere boss Ron Zwanziger (who's knowledge is arguably greater than most institutions), appears to have a lot of faith that the current share price is offering a decent opportunity.

Ekf Diagnostics Most Recent Trade

Trade Type Trade Size Trade Price Trade Date Trade Time Currency
AT 35,000 22.50 28 Aug 2015 15:36:31 GBX


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 150828 23:15